ABEO

Abeona Therapeutics Inc. (ABEO) | Rumor.io

Abeona Therapeutics

ABEO

Attention (50-day avg)0%

Attention rank (50-day avg)#1,460

Bullish sentiment (50-day avg)82%

Price to earnings ratio7.83

Market capitalization302.5M

Earnings per share-1.21

Dividend yield (TTM)—

Revenue (annual)5.8M

Net income (annual)71.2M

Social

What share of all stock conversation is about ABEO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Sep 18

Abeona Therapeutics (ABEO) has been granted up to 10% royalty on sales of FAYUVI, a gene therapy for Sanfilippo syndrome type A, with a potential $30M milestone payment upon approval.
Ultragenyx's FDA approval of FAYUVI is a significant milestone for patients and families affected by Sanfilippo syndrome type A, with Abeona's CEO stating that the company was privileged to help advance the program from its academic origins into clinical development.
Cantor Fitzgerald has raised ABEO's stock price target to $30 from $28, maintaining an Overweight rating on the shares, with a current price of $5.59.

Generated by AI

Sentiment

Of the messages about ABEO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +9.26	86.25% +5.59	86.01% -1.68
Bearish	—	0% -9.26	13.75% -5.59	13.99% +1.68

Bullish· Aug 13

The company has successfully treated 12 cumulative patients since launch, including 3 already completed in Q3 to-date, with the S-curve rollout executing perfectly on schedule.
Abeona has built an exceptional network of 7 fully activated Qualified Treatment Centers (QTCs), with elite players like CHOP and Cincinnati Children’s controlling roughly 40% of the U.S. addressable market.
The company possesses multiple years of pure operational survival runway with zero structural reason to dilute shareholders, with a cash fortress of $146.8 million and a growing accounts receivable pipeline.

Bearish· May 13

The company's treatment has a high list price of $3.1 million, which may be a barrier to adoption.
The company's revenue projections are overly optimistic, with some estimates suggesting that the company may not reach profitability until 2027.
The company's high expenses, including sales commissions and R&D costs, may eat into its already thin profit margins, making it difficult to sustain growth.

Generated by AI

Topics

Of the messages about ABEO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	70.75%	63.49%
Earnings	—	0%	2.72%	17.6%
Technical Analysis	—	0%	2.04%	10.45%
Analysts	—	0%	24.49%	8.35%
Controversies	—	0%	0%	0.11%
Macro	—	0%	0%	0%

Earnings· Mar 27

Abeona Therapeutics Inc. ($ABEO) reports FQ4 earnings of -19c EPS and $0.22M revenue.
$ABEO misses the Estimize EPS consensus by 5c and the Estimize revenue consensus by $0.02M.
$ABEO hosts Q1 earnings call today at 10:00 AM Eastern, streaming live or on replay.

Analysts· Jun 5

Seaport Global Securities initiated coverage of Abeona Therapeutics ($ABEO) with a buy rating and a $29 price target.
HC Wainwright analysts gave Abeona Therapeutics ($ABEO) a $30 price target and reaffirmed their buy rating.
ValuEngine upgraded Abeona Therapeutics ($ABEO) to a buy rating.

Announcements· Nov 12

Abeona Therapeutics has optimized the product release assay for ZEVASKYN, and commercial product treatment is now anticipated to start in 4Q'25.
The company has strong and growing patient demand for ZEVASKYN, with over 30 eligible patients identified and 12 patients in the process of scheduling treatments.
Abeona has a cash position of $207.5 million, expected to be sufficient to fund current and planned operations for over two years, and has secured a permanent J-code for ZEVASKYN.

Technical Analysis· Sep 3

$ABEO has been trading in a strong upward trend, with a recent breakout above $2.80 and a 52-week high volume.
The 20 EMA has been held perfectly on the 5-minute and 1-minute charts, with some traders scaling out on the break of the high of day (HOD) at $2.78.
The stock is nearing its 52-week high volume, with some traders expecting a pullback or consolidation before the next leg up, while others are looking for a close above $3.50 to confirm a key breakout.

Generated by AI

Community

Of the messages about ABEO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	78.13%	72.77%	67.59%
Newcomers	100%	21.88%	27.23%	32.41%

Regulars· Sep 18

The FDA approval of UX111, a gene therapy for Sanfilippo syndrome type A, is a significant milestone for Abeona Therapeutics and its partner Ultragenyx, with Abeona expecting to receive up to 10% royalty from sales.
The approval is expected to have a positive impact on Abeona's profitability, with the company's CEO stating that the journey to this achievement is a testament to years of scientific innovation and determination.
Cantor Fitzgerald has raised Abeona's stock price target to $30 from $28, citing the approval of UX111 as a major factor, and analysts maintain a Strong Buy consensus on the biotech company.

Newcomers· Aug 13

Newcomers to the stock are focused on the recent price drop, with some expressing optimism that the price is a buying opportunity.
The Q2 revenue of $11.4M, a 31% increase quarter-over-quarter, is seen as a positive development, with some analysts noting that the revenue growth is a sign of a strong product.
The company's net loss widened to $0.35/share, and the operating loss was $13.7M, which is a concern for some investors, but others see it as a necessary step in the company's growth.

Generated by AI

News

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference. Madhav Vasanthavada, Abeona’s senior vice president

7d agoYahoo Finance

Also Discussed

Investors talking about ABEO also mention

#	Name	Attention
1	Krystal Biotech, Inc.KRYS	0%0
2	Ultragenyx Pharmaceutical Inc.RARE	0.01%+0.01
3	SGMO - Sangamo Therapeutics, Inc.	——
4	Boundless Bio Inc.BOLD	0%0
5	SES AI CorporationSES	0%0
6	NLTX - Neoleukin Therapeutics, Inc.	——
7	Perspective Therapeutics Inc.CATX	0%+0
8	NTBL - Notable Labs, Ltd.	——
9	Regenxbio Inc.RGNX	0%+0
10	AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETFSIXD	0%0

Abeona Therapeutics Inc.

Healthcare
Biotechnology

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for serious rare diseases. Its current portfolio centers on ZEVASKYN, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, alongside a pipeline of adeno-associated virus-based programs for ophthalmic and other genetic disorders. The company also develops engineered T-cell and viral vector technologies designed to address high-unmet-need conditions in oncology and rare disease settings. Abeona Therapeutics operates from Cleveland, Ohio, with a fully integrated cGMP manufacturing facility that supports commercial production and clinical development activities. The company serves the biotechnology and advanced therapies market, where it plays a specialized role in translating genetic medicine into targeted treatments for patients with limited therapeutic options.

Website

Location

6555 Carnegie Avenue

Cleveland, OH, 44103

United States

Social

What share of all stock conversation is about ABEO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Sep 18

Abeona Therapeutics (ABEO) has been granted up to 10% royalty on sales of FAYUVI, a gene therapy for Sanfilippo syndrome type A, with a potential $30M milestone payment upon approval.
Ultragenyx's FDA approval of FAYUVI is a significant milestone for patients and families affected by Sanfilippo syndrome type A, with Abeona's CEO stating that the company was privileged to help advance the program from its academic origins into clinical development.
Cantor Fitzgerald has raised ABEO's stock price target to $30 from $28, maintaining an Overweight rating on the shares, with a current price of $5.59.

Generated by AI

Sentiment

Of the messages about ABEO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +9.26	86.25% +5.59	86.01% -1.68
Bearish	—	0% -9.26	13.75% -5.59	13.99% +1.68

Bullish· Aug 13

The company has successfully treated 12 cumulative patients since launch, including 3 already completed in Q3 to-date, with the S-curve rollout executing perfectly on schedule.
Abeona has built an exceptional network of 7 fully activated Qualified Treatment Centers (QTCs), with elite players like CHOP and Cincinnati Children’s controlling roughly 40% of the U.S. addressable market.
The company possesses multiple years of pure operational survival runway with zero structural reason to dilute shareholders, with a cash fortress of $146.8 million and a growing accounts receivable pipeline.

Bearish· May 13

The company's treatment has a high list price of $3.1 million, which may be a barrier to adoption.
The company's revenue projections are overly optimistic, with some estimates suggesting that the company may not reach profitability until 2027.
The company's high expenses, including sales commissions and R&D costs, may eat into its already thin profit margins, making it difficult to sustain growth.

Generated by AI

Topics

Of the messages about ABEO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	70.75%	63.49%
Earnings	—	0%	2.72%	17.6%
Technical Analysis	—	0%	2.04%	10.45%
Analysts	—	0%	24.49%	8.35%
Controversies	—	0%	0%	0.11%
Macro	—	0%	0%	0%

Earnings· Mar 27

Abeona Therapeutics Inc. ($ABEO) reports FQ4 earnings of -19c EPS and $0.22M revenue.
$ABEO misses the Estimize EPS consensus by 5c and the Estimize revenue consensus by $0.02M.
$ABEO hosts Q1 earnings call today at 10:00 AM Eastern, streaming live or on replay.

Analysts· Jun 5

Seaport Global Securities initiated coverage of Abeona Therapeutics ($ABEO) with a buy rating and a $29 price target.
HC Wainwright analysts gave Abeona Therapeutics ($ABEO) a $30 price target and reaffirmed their buy rating.
ValuEngine upgraded Abeona Therapeutics ($ABEO) to a buy rating.

Announcements· Nov 12

Abeona Therapeutics has optimized the product release assay for ZEVASKYN, and commercial product treatment is now anticipated to start in 4Q'25.
The company has strong and growing patient demand for ZEVASKYN, with over 30 eligible patients identified and 12 patients in the process of scheduling treatments.
Abeona has a cash position of $207.5 million, expected to be sufficient to fund current and planned operations for over two years, and has secured a permanent J-code for ZEVASKYN.

Technical Analysis· Sep 3

$ABEO has been trading in a strong upward trend, with a recent breakout above $2.80 and a 52-week high volume.
The 20 EMA has been held perfectly on the 5-minute and 1-minute charts, with some traders scaling out on the break of the high of day (HOD) at $2.78.
The stock is nearing its 52-week high volume, with some traders expecting a pullback or consolidation before the next leg up, while others are looking for a close above $3.50 to confirm a key breakout.

Generated by AI

Community

Of the messages about ABEO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	78.13%	72.77%	67.59%
Newcomers	100%	21.88%	27.23%	32.41%

Regulars· Sep 18

The FDA approval of UX111, a gene therapy for Sanfilippo syndrome type A, is a significant milestone for Abeona Therapeutics and its partner Ultragenyx, with Abeona expecting to receive up to 10% royalty from sales.
The approval is expected to have a positive impact on Abeona's profitability, with the company's CEO stating that the journey to this achievement is a testament to years of scientific innovation and determination.
Cantor Fitzgerald has raised Abeona's stock price target to $30 from $28, citing the approval of UX111 as a major factor, and analysts maintain a Strong Buy consensus on the biotech company.

Newcomers· Aug 13

Newcomers to the stock are focused on the recent price drop, with some expressing optimism that the price is a buying opportunity.
The Q2 revenue of $11.4M, a 31% increase quarter-over-quarter, is seen as a positive development, with some analysts noting that the revenue growth is a sign of a strong product.
The company's net loss widened to $0.35/share, and the operating loss was $13.7M, which is a concern for some investors, but others see it as a necessary step in the company's growth.

Generated by AI

Abeona Therapeutics

Social

Sep 18

Bullish· Aug 13

Bearish· May 13

Earnings· Mar 27

Analysts· Jun 5

Announcements· Nov 12

Technical Analysis· Sep 3

Regulars· Sep 18

Newcomers· Aug 13

Abeona Therapeutics CEO Seshadri sells $101,091 in shares

Abeona Therapeutics CFO Joseph Vazzano sells $47,385 in company stock

Abeona Therapeutics CCO Madhav sells $25,272 in stock

Abeona Therapeutics SVP sells $34,681 in company stock

Abeona Therapeutics stock reiterated at Buy by H.C. Wainwright

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

Also Discussed

Abeona Therapeutics Inc.

Company Information

Location

Abeona Therapeutics CEO Seshadri sells $101,091 in shares

Abeona Therapeutics CFO Joseph Vazzano sells $47,385 in company stock

Abeona Therapeutics CCO Madhav sells $25,272 in stock

Abeona Therapeutics SVP sells $34,681 in company stock

Abeona Therapeutics stock reiterated at Buy by H.C. Wainwright

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

Also Discussed

Social

Sep 18

Bullish· Aug 13

Bearish· May 13

Earnings· Mar 27

Analysts· Jun 5

Announcements· Nov 12

Technical Analysis· Sep 3

Regulars· Sep 18

Newcomers· Aug 13